Cancer Network
Spotlight
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer UpdatesCancerNetwork® Inaugural Face-OffContemporary Concepts in Hematologic OncologyInsights from Experts at Mayo Clinic on Translating Evidence to Clinical PracticeOptimizing Outcomes in Patients with HER2+ Metastatic Breast CancerReal-World Evidence in NSCLC Guides Clinical Decisions Targeting NSCLC with Uncommon EGFR Mutations
Clinical
View MoreAcute Myeloid LeukemiaBrain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
News
Clinical TopicsIntegrative CareGlobal BulletinAll NewsApproval Alert
Media
2 Minute DrillAround the PracticeAwareness MonthBetween the LinesClinical ConsultExpert InterviewsFace OffMedical World NewsMorning RoundsOncViewPodcastsReadout 360Year in Review
Conferences
Publications
All JournalsFor AuthorsTumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary ConceptsInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
Subscribe
eNewsletterPrint Subscription

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2023 MJH Life Sciences and Cancer Network. All rights reserved.

Advertisement
Spotlight
  • 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
  • CancerNetwork® Inaugural Face-Off
  • Contemporary Concepts in Hematologic Oncology
  • Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
  • Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
  • Real-World Evidence in NSCLC Guides Clinical Decisions
  • Targeting NSCLC with Uncommon EGFR Mutations
ClinicalSee All >
  • Acute Myeloid Leukemia
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Gynecologic Cancer
  • Hematology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Pediatric Cancers
  • Skin Cancer
  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.

Multiple Myeloma Face-Off: Ken Shain, MD, PhD, and Ravi Vij, MD, MBA, on ASH 2022

EP. 1: Expert Recaps Recent Research and Evolving Paradigms in Multiple Myeloma

December 19th 2022

Ken Shain, MD, PhD, discussed some of the research in multiple myeloma that was featured in a recent FaceOff program, and how these recent advances may change the standard of care.

EP. 2: Expert Highlights Practice-Changing Effects of Immunotherapies in Multiple Myeloma

December 19th 2022

Ken Shain, MD, PhD, spoke about the dramatic impact of novel immunotherapies in the multiple myeloma treatment landscape, as well as other updates from the 2022 ASH Annual Meeting and Exposition.

EP. 3: Forecasting the Future of Multiple Myeloma

December 19th 2022

Ken Shain, MD, PhD, provides an overview of developments on the horizon in multiple myeloma.

EP. 4: Access, Access, Access: Unmet Needs in Multiple Myeloma

December 20th 2022

Ken Shain, MD, PhD, pinpoints the critical, lingering gaps in patient access to cellular immunotherapies in multiple myeloma.

Advertisement
Advertisement